Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (8)

« Back to Publications

The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program.

Fagnan A. et al, (2024), Hemasphere, 8

The NFIA-ETO2 fusion blocks erythroid maturation and induces pure erythroid leukemia in cooperation with mutant TP53.

Piqué-Borràs M-R. et al, (2023), Blood, 141, 2245 - 2260

High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia.

Aid Z. et al, (2023), Leukemia, 37, 571 - 579

Molecular Landscapes and Models of Acute Erythroleukemia.

Fagnan A. et al, (2021), Hemasphere, 5

Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.

Fagnan A. et al, (2020), Blood, 136, 698 - 714

NUP98 and KMT2A: usually the bride rather than the bridesmaid.

Fagnan A. and Mercher T., (2020), Haematologica, 105, 1757 - 1760

Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia.

Lopez CK. et al, (2019), Cancer Discov, 9, 1736 - 1753

PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.

Hanna JA. et al, (2018), Oncogene, 37, 1991 - 2007